Innovation Zone

WHAT IS THE INNOVATION ZONE?

The 2024 Innovation Zone is a dedicated space within the ISCT 2024 exhibit hall where disruptive early-stage cell and gene companies can showcase their technology to over 2,000+ cell and gene therapy (CGT) translation experts. This space offers an affordable and accessible opportunity for thriving start ups to exhibit alongside leading global CGT organizations.

ATTEND THE INNOVATION ZONE PITCHING SESSION

ISCT 2024 will host two interactive Innovation Zone pitching sessions open to all delegates to attend. Here, our Innovation Zone start-ups will have the chance to showcase their technologies to a panel of globally recognized CGT experts and life science investors, receiving valuable feedback to propel their growth. Attend these sessions to hear firsthand about the innovations on the horizon of the sector.

Thursday, May 30, 2024
08:00–09:00

Friday, May 31, 2024
09:15–10:15


MEET THIS YEAR'S
PARTICIPATING COMPANIES

EQUIPMENT / DEVICES PROVIDER

AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, analytics, and cell therapy processing markets. AcouSort’s components allow for automated refinement of biological samples such as blood or cell preparations, providing instrumentation manufacturers with a state-of-the-art ability to integrate sample processing steps that traditionally must be performed manually.

VISIT WEBSITE

EQUIPMENT / DEVICES PROVIDER

Aenitis devices and module type package engineering services fits with needs of Cell and Gene Therapy Units, Biopharma, Biotechs, CDMOs and Research labs.

Aenitis promotes Mitis™, a device for high flow gentle cell handling, with technological approach that permits to handle cell in continue with no mechanical stress and in sterile condition which meet GMP compliance for bioprocessing requirement.

High flow acoustic cell handling appears as an alternative to the limits of legacy bioprocessing technologies.

Please visit our booth at ISCT the 2024 Innovation Zone! We will be pleased to explore possibilities to organise first trials with you!

VISIT WEBSITE

EQUIPMENT / DEVICES PROVIDER

Allegrow Biotech started as a spinoff start-up from the biomaterials laboratory at the Hong Kong University of Science & Technology, specializing in modulating and manipulating immune cells using biomaterial-based approaches. We have developed a scalable synthetic cell platform that mimics various cell types and address countless applications – from research tools to manufacturing therapeutics, with immediate usage in the activation and expansion of T cells in CAR-T therapies.

VISIT WEBSITE

EQUIPMENT / DEVICES PROVIDER

Cellular Vehicles has developed the Odyssey System, a flexible and accessible automation platform for cell/gene therapy delivery. The Odyssey System takes the entire infrastructure required to deliver a CGT to patients, and puts it into a small box that can be deployed at any care site.

VISIT WEBSITE

EQUIPMENT / DEVICES PROVIDER

Cytomos is a dynamic early-stage company developing ground-breaking cell analysis systems that can be used alone or alongside conventional technologies such as flow cytometry. The Cytomos AuraCyt™ technology is a revolutionary label-free cell analytics platform which leverages cost-efficient microchip technology, providing streamlined testing strategies and economically viable cell therapies. The technology closely monitors a broad range of individual cell features simultaneously and collects data on intrinsic cellular properties in real-time, delivering unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications.

VISIT WEBSITE

CDMO

ExoXpert is an exosome specialized CDMO based in Belgium and providing development and manufacturing capabilities. ExoXpert is a subsidiary of Exo Biologics, the first company to have ever been authorized to start clinical phase I/II in EU with MSC-exosomes thanks to the ExoPulse manufacturing platform. ExoXpert is making the GMP approved ExoPulse platform accessible to everyone in order to fast track exosome process development and clinical access.

VIEW WEBSITE

THERAPEUTIC DEVELOPER

Hemera, spin-off of the Universities of Verona and Milan funded in 2021, is a biotech company specialized in regenerative medicine for neurological diseases. Responding to the unsolved issue of spinal cord lesions, Hemera develops an autologous cell therapy for tissue regeneration.

VIEW WEBSITE

THERAPEUTIC PROVIDER

KyooBe Tech, an aspiring subsidiary company of the Bausch+Ströbel Group, focuses on commercializing innovative pharmaceutical production technologies. Our first product line, eFIT, will enter the market in 2024, using low-energy electron irradiation as a new application for vaccine production and viral clearance. Additionally, we develop with MOSAIC a modular manufacturing platform for personalized medicine that enables individual cell therapy production on an industrial scale.

VISIT WEBSITE

THERAPEUTIC DEVELOPER

VascVersa is a Northern Irish early-stage regenerative medicine company developing new cell therapies that promote vascular regeneration and repair. Building on over ten year’s academic research at Queen’s University Belfast, the company has developed a proprietary technology for the manufacture of Angicyte - a robust, highly-scalable, autologous, cell-product with a proven capacity to make new blood vessels and promote healing. VascVersa is developing therapies to treat major unmet clinical needs caused by ischemic conditions.

The company is currently developing their first product for treating chronic non healing wounds with a focus on Diabetic Foot Ulcers (DFUs). During 2024 the company is seeking Series A funding for a First In Human clinical study for DFUs scheduled for early 2026. The company is exploring the potential for Angicyte to treat other ischemic diseases including ischemic heart, brain and eye diseases and would be keen to build strategic partnerships in these fields and explore co-development opportunities.

VISIT WEBSITE

CDMO / CMO / CRO

VintaBio is a Contract Manufacturing and Development Organization (CDMO) specializing in developing and manufacturing premium-grade viral vectors for cell and gene therapy. The Company operates from a state-of-the-art, new 22,500 square foot facility in Philadelphia, PA created specifically to facilitate intensified manufacturing. With over 120 years’ combined experience in the cell and gene therapy space, VintaBio has a unique understanding of the process requirements to develop and manufacture gene therapy products throughout the entire drug lifecycle. Founded in 2020 by cell and gene therapy pioneers, Junwei Sun and Dr. Shangzhen Zhou, VintaBio has to date raised $64 million in venture funding.

VISIT WEBSITE

WHO ARE THE INNOVATION ZONE COMPANIES?

For companies to participate in the ISCT Innovation Zone, they must:

  • Have been established for less than 5 years
  • Not previously exhibited at an ISCT meeting
  • Maintain a staff size of fewer than 25 full-time equivalent